Profile data is unavailable for this security.
About the company
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
- Revenue in USD (TTM)0.00
- Net income in USD-232.75m
- Incorporated2009
- Employees107.00
- LocationKodiak Sciences Inc1200 PAGE MILL RDPALO ALTO 94304United StatesUSA
- Phone+1 (650) 281-0850
- Fax+1 (302) 636-5454
- Websitehttps://kodiak.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Elevation Oncology Inc | 0.00 | -39.35m | 148.07m | 29.00 | -- | 1.85 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.26m | 149.17m | 18.00 | -- | 2.86 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Capricor Therapeutics Inc | 27.10m | -24.31m | 152.70m | 101.00 | -- | 8.23 | -- | 5.63 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Citius Pharmaceuticals Inc | 0.00 | -37.35m | 153.97m | 22.00 | -- | 1.71 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Galectin Therapeutics Inc | 0.00 | -44.78m | 154.13m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
Personalis Inc | 74.15m | -92.61m | 154.78m | 223.00 | -- | 1.27 | -- | 2.09 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Kodiak Sciences Inc | 0.00 | -232.75m | 157.08m | 107.00 | -- | 0.6511 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 158.07m | 140.00 | -- | 20.44 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
Quantum-Si Inc | 1.29m | -91.82m | 158.83m | 159.00 | -- | 0.6259 | -- | 123.61 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 160.90m | 68.00 | -- | 10.69 | -- | 23.05 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Adverum Biotechnologies Inc | 0.00 | -112.90m | 161.07m | 121.00 | -- | 0.8835 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Repare Therapeutics Inc | 97.86m | -45.69m | 165.11m | 179.00 | -- | 0.7057 | -- | 1.69 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Achieve Life Sciences Inc | 0.00 | -27.32m | 165.87m | 22.00 | -- | 3.35 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
Context Therapeutics Inc | 0.00 | -21.32m | 166.50m | 5.00 | -- | 4.20 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 28 Jun 2024 | 17.31m | 32.95% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.83m | 5.39% |
Acadian Asset Management LLCas of 31 Mar 2024 | 1.72m | 3.28% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.63m | 3.10% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 1.61m | 3.07% |
SilverArc Capital Management LLCas of 31 Mar 2024 | 1.24m | 2.36% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 1.04m | 1.99% |
ICONIQ Capital LLCas of 31 Mar 2024 | 1.02m | 1.94% |
Newtyn Management LLCas of 31 Mar 2024 | 1.00m | 1.90% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 781.54k | 1.49% |